News | August 08, 2022
Valiant Organics to start production of OAP and Pharma Intermediates
Both the plants have a total Capex of Rs. 75 crore and expected production timeline is Q3 FY23
Both the plants have a total Capex of Rs. 75 crore and expected production timeline is Q3 FY23
With this expansion, the Grand Island site provides redundant capacity to support global supply of media and further extends the site’s capabilities to produce the high-quality technology and materials needed for the development and commercial manufacturing of vaccines and biologic therapies
Company will invest approximately ¥16 billion to increase production capacity by approximately 70% to ensure a stable supply
Lupin is the 6th largest company in the Indian Pharmaceutical Market
Despite the price increases for raw materials and logistics, EBITDA pre rose organically by 3.2% to € 1,782 million
The CSC shall hold Market Authorisation (MA) to sell SRL's BUSALFAN, API exclusively in China territory.
Under the PMBJP, till 30.06.2022, 8742 PMBJKs have been opened across the country including Government Hospitals and Government premises.
India exported Bulk Drugs/Drug Intermediates worth Rs. 33,320 crore in financial year 2021-22.
He was appointed a Board member and the Chairman in 2012.
Strides is the first Indian company to get approval for the product.
Subscribe To Our Newsletter & Stay Updated
